Vermont-based medtech startup Pacto Medical has closed an oversubscribed seed round and secured a U.S. utility patent for its compact prefilled syringe technology, marking two major milestones in the company’s effort to modernize injectable drug delivery.
The seed funding round drew strong interest from investors across healthcare, medtech, pharma, and social impact sectors. The new capital will be used to expand the company’s team, strengthen partnerships with pharmaceutical manufacturers and distributors, and accelerate the market launch of its prefilled syringe platform.
At the same time, Pacto Medical was awarded U.S. Patent No. 12,440,623 B2, covering its proprietary syringe design. The patent solidifies the company’s intellectual property position and underscores the novelty of its approach to simplifying and improving drug delivery.
“These achievements mark a pivotal moment for Pacto Medical,” said Ian Speers, CEO and Co-Founder. “The overwhelming investor response demonstrates strong confidence in our technology, and our utility patent provides a solid foundation for long-term competitive advantage. We’re committed to making injectable drug delivery safer, simpler, more affordable, more sustainable, and more equitably accessible around the world.”
The company’s compact prefilled syringe is designed to improve healthcare access and affordability by reducing waste, cost, and complexity in injectable therapies, an area often constrained by bulky devices and manufacturing inefficiencies.
With funding secured and patent protection in place, Pacto Medical is now pursuing strategic collaborations to bring its syringe platform to a range of therapeutic applications.
